Rezolute

RZLT

Market cap $339M

RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.

In a recent update, Rezolute shared insights from its March 17 meeting with the FDA regarding its Phase 3 sunRIZE trial for ersodetug, aimed at treating congenital hyperinsulinism.

REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI.

NEW YORK--(BUSINESS WIRE)---- $RZLT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. Rezolute, Inc. shares tumbled sharply on December 11, 202.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310).  [You may also click here for additional information] NEW YORK, March 5, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Citizens Life Sciences Conference, taking place March 10-11, 2026, in Miami, FL.

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310).  [You may also click here for additional information] NEW YORK, Feb. 28, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - February 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).